The following is a list of the most commonly prescribed drugs. It represents an abbreviatedversion of the drug list (formulary) that is at the core of your prescription-drug benefit plan. The list is not all-inclusive and does not guarantee coverage. In addition to using this list,you are encouraged to ask your doctor to prescribe generic drugs whenever appropriate. 2013 Express Scripts PLEASE NOTE: The symbol * next to a drug signifies that it is subject to nonformulary status when a generic is available throughout the year. Not all the drugs listed are covered by all National Preferred Formulary prescription-drug benefit programs; check your benefit materials for the specific drugs covered and the copayments for your prescription-drug benefit program. For specific For University of New Mexico questions about your coverage, please call the phone number printed on your ID card. A D B G
GENOTROPIN [INJ] [PA] [SP] lisinopril, /hctz
O H
HUMATROPE [INJ] [PA] [SP] M E C I P J F K N
naproxen, naproxen sodium potassium chloride, er
L THIS DOCUMENT LIST IS EFFECTIVE JANUARY 1, 2013 THROUGH DECEMBER 31, 2013. THIS LIST IS SUBJECT TO CHANGE. If your drug is not listed visit our website at www.express-scripts.com for a complete and updated listing. 2013 Express Scripts Holding Company All Rights Reserved PRMTNMMANP-13 (04/05/13) Examples of Nonformulary Medications With Selected Formulary Alternatives
The following is a list of some nonformulary brand-name medications with examples of selected alternatives that are on the formulary.
Column 1 lists examples of nonformulary medications.
Column 2 lists some alternatives that can be prescribed. Nonformulary Formulary Alternative Nonformulary Formulary Alternative Q
balsalazide, Asacol/HD, Delzicol, Lialda,
Genotropin [PA][SP], Humatrope [PA][SP],
R U
ciprofloxacin/er, levofloxacin, ofloxacin,
V
Genotropin [PA][SP], Humatrope [PA][SP],
ciprofloxacin/er, levofloxacin, ofloxacin,
S
Genotropin [PA][SP], Humatrope [PA][SP],
ciprofloxacin/er, levofloxacin, ofloxacin,
80 MG, 105 MG, 115 MG W
FLOVENT DISKUS, HFA Asmanex, Pulmicort Flexhaler, Qvar
Genotropin [PA][SP], Humatrope [PA][SP],
X Z
The symbol ^ next to a drug name indicates it has a zero dollar copay.
The symbol [INJ] next to a drug name indicates that the drug is available in injectable form only.
The symbol [PA] next to a drug name indicates that a Prior Authorization is required for coverage.
The symbol [SP] next to a drug name indicates it is a CuraScript specialty medication and is a Tier 4 copay. T
The symbol [ST] next to a drug name indicates that Step Therapy may apply to some or all strengths of the drug. For the member: Generic medications contain the same active ingredients as their corresponding brand-name medications,
although they may look different in color or shape. They have been FDA-approved under strict standards. For the physician: Please prescribe preferred products and allow generic substitutions when medically appropriate. Thank you.
Brand-name drugs are listed in CAPITAL letters and are Tier 2 copays.
Generic drugs are listed in lower case letters and are Tier 1 copays. THIS DOCUMENT LIST IS EFFECTIVE JANUARY 1, 2013 THROUGH DECEMBER 31, 2013. THIS LIST IS SUBJECT TO CHANGE. If your drug is not listed visit our website at www.express-scripts.com for a complete and updated listing. 2013 Express Scripts Holding Company All Rights Reserved PRMTNMMANP-13 (04/05/13)
Title Incremental Cost-Effectiveness (ICE) Statistical Inference from Two Unbiased SamplesAuthor Bob Obenchain <wizbob@att.net>Maintainer Bob Obenchain <wizbob@att.net>Description Given two unbiased samples of patient level data on cost and effectivenessfor a pair of treatments, make head-to-head treatment comparisons by (i) generating thebivariate bootstrap resampling distribution
REGISTERED NURSES ASSOCIATION OF THE NORTHWEST TERRITORIES AND NUNAVUT PRESCRIPTIVE AUTHORITY GUIDELINES FOR NWT PRIMARY HEALTH CARE NURSE PRACTITIONERS These Guidelines form an addendum to the August 2005 RNANT/NU PracticeGuidelines for Primary Health Care Nurse Practitioners, approved by the Ministerof Health and Social Services (the Minister), and are approved by the Ministerunder